Clinical Trials Logo

Clinical Trial Summary

International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF)


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Heart Failure
  • Heart Failure With Reduced Ejection Fraction (HFrEF)

NCT number NCT03877237
Study type Interventional
Source AstraZeneca
Contact
Status Completed
Phase Phase 3
Start date April 9, 2019
Completion date March 7, 2020

See also
  Status Clinical Trial Phase
Completed NCT05328752 - Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF) Phase 1
Recruiting NCT05420012 - The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation Phase 4
Active, not recruiting NCT05136820 - Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study N/A
Not yet recruiting NCT04304560 - Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial Phase 2
Completed NCT04180696 - Mid-Q Response Study N/A
Recruiting NCT04331769 - Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study N/A
Recruiting NCT04860596 - The Effectiveness of Collaborative Health Management Model on Heart Failure Patient N/A